Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 10CNS 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 6Head & Neck 6Gastrointestinal 6Endocrine 4Tumor-Agnostic 3Sarcoma 2Other solid neoplasm 1Myeloid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Standard of Care 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Gemcitabine 6Cyclophosphamide 6Capecitabine 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Surveys and Questionnaires 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
trametinib × Tumor-Agnostic × 90 days × Clear all
NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT02079740 2026-05-28

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT04116541 2026-04-24

MegaMOST

Centre Leon Berard

Phase 2 Recruiting
455 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡